The Technical Analyst
Aileron Therapeutics Inc [ALRN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aileron Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
17.65% $5.00
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 84.86 mill |
| EPS: | -2.85 |
| P/E: | -1.750 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 16.97 mill |
| Avg Daily Volume: | 0.0360 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.750 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.30x |
| Company: PE -1.750 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0038 (-99.92%) $-5.00 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.53 - 5.49 ( +/- 9.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | Von Rickenbach Josef H | Buy | 2 725 | Stock Option (right to buy) |
| 2024-02-28 | Ambros Reinhard J. | Buy | 2 725 | Stock Option (right to buy) |
| 2024-03-25 | Garner Charles | Sell | 349 750 | Stock Option (right to buy) |
| 2024-03-25 | Garner Charles | Sell | 25 597 | Stock Option (right to buy) |
| 2024-03-05 | Windsor James Brian | Buy | 2 000 | Common Stock |
| INSIDER POWER |
|---|
| -81.09 |
| Last 95 transactions |
| Buy: 24 990 503 | Sell: 1 525 640 |
Forecast:
16:00 - $4.95
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.95
Forecast 2: 16:00 - $4.95
Forecast 3: 16:00 - $4.95
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.00 (17.65% ) |
| Volume | 1.751 mill |
| Avg. Vol. | 0.0360 mill |
| % of Avg. Vol | 4 861.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALRN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Latest Press Releases
2024-04-15 17:20:00 - Press Release
Aileron Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Topline results from phase 1b study of lti-03, a novel caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024
2024-03-12 08:00:00 - Press Release
Aileron Therapeutics Announces Ceo Transition
Current president and chief operating officer, brian windsor, ph.d., appointed chief executive officer dr. windsor to lead aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases waltham, mass.
2024-02-15 16:05:00 - Press Release
Aileron Therapeutics And Pulmonary Care Experts To Discuss The Potential Implications Of Lti-03 For Idiopathic Pulmonary Fibrosis In Virtual Key Opinion Leader Event
Topline results from phase 1b study of lti-03, aileron's novel caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 topline results from phase 1b study of lti-03, aileron's novel caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024
2024-02-01 16:30:00 - Press Release
Aileron Therapeutics To Host Key Opinion Leader Event On February 15, 2024
Panel discussion will highlight lti-03, aileron's novel caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis panel discussion will highlight lti-03, aileron's novel caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
2023-10-31 12:30:00 - Press Release
Aileron Therapeutics Announces Acquisition Of Lung Therapeutics
Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including lti-03, a caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (ipf) financing proceeds of approximately $18 million from a private placement anticipated to fund completion of the ongoing phase 1b clinical study of lti-03 in ipf and for general corporate purposes company to host conference call today at 1:30 p.m. edt waltham, mass.
Latest News
2023-04-04 11:24:19 - Zacks Investment Research
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Aileron Therapeutics, Inc. (ALRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2023-03-14 11:26:56 - Zacks Investment Research
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Aileron Therapeutics, Inc. (ALRN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2022-12-29 13:32:11 - Zacks Investment Research
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Aileron Therapeutics, Inc. (ALRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-11-04 13:34:24 - Zacks Investment Research
Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade
Aileron Therapeutics, Inc. (ALRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2022-09-22 08:00:00 - GlobeNewsWire
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.
2022-08-08 06:00:00 - PennyStocks
Penny Stocks to Buy on August 8th? 3 to Watch
Here's what you need to know about buying penny stocks on August 8th The post Penny Stocks to Buy on August 8th? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-08-07 11:30:00 - PennyStocks
How to Trade Penny Stocks in August 2022
What you need to know about trading penny stocks in August The post How to Trade Penny Stocks in August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-19 06:40:42 - InvestorPlace
3 Oversold Biotech Stocks to Buy Now
Looking for oversold biotech stocks? These three have all seen significant drops this year despite promising catalysts for the future.
2022-05-17 07:00:00 - GlobeNewsWire
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.
2022-04-21 11:19:10 - Zacks Investment Research
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.